obesity Archives -

Digital/ News/ News/ News/ Patients

Novo Nordisk, Kry partner on digital programme for obesity

Phil Taylor digital, digital health, Kry, Novo Nordisk, obesity, patient support, Saxenda, Wegovy 0 Comment

Digital health specialist Kry has teamed up with pharma group Novo Nordisk on the development of resources that

Novo Nordisk, Kry partner on digital programme for obesity

https://pharmaphorum.com/news/novo-nordisk-kry-partner-on-digital-programme-for-obesity/

News/ News/ News/ Patients/ R&D

Alnylam finds belly fat gene and drug target in UK Biobank study

Phil Taylor Alnylam Pharmaceuticals, Biobank, cardiovascular disease, Diabetes, Gene, obesity 0 Comment

Alnylam Pharma has made a name for itself, developing gene-silencing therapies for rare disorders, but its latest discovery

Alnylam finds belly fat gene and drug target in UK Biobank study

https://pharmaphorum.com/news/alnylam-finds-belly-fat-gene-and-drug-target-in-uk-biobank-study/

News/ News/ R&D

Lilly fires a broadside at Novo Nordisk’s obesity ambitions

Phil Taylor Eli Lilly, Novo Nordisk, obesity, tirzepatide, Wegovy 0 Comment

Denmark’s Novo Nordisk has been almost single-handedly rebuilding the market for drugs to treat obesity over the last

Lilly fires a broadside at Novo Nordisk’s obesity ambitions

https://pharmaphorum.com/news/lilly-fires-a-broadside-at-novo-nordisks-obesity-ambitions/

News/ News/ Sales and Marketing

Novo Nordisk eyes obesity sales of $3.7bn in 2025 thanks to Wegovy

Phil Taylor Novo Nordisk, obesity, Saxenda, Wegovy 0 Comment

Novo Nordisk’s rollout of obesity therapy Wegovy has been beset by production problems, but the company says these

Novo Nordisk eyes obesity sales of $3.7bn in 2025 thanks to Wegovy

https://pharmaphorum.com/news/novo-nordisk-eyes-obesity-sales-of-3-7bn-in-2025-thanks-to-wegovy/

Market Access/ News/ News

Novo Nordisk gets NICE okay for obesity drug Wegovy

Phil Taylor HEOR, NHS, NICE, Novo Nordisk, obesity, Wegovy 0 Comment

Novo Nordisk’s new obesity therapy Wegovy has been recommended for routine NHS use by UK cost-effectiveness watchdog NICE,

Novo Nordisk gets NICE okay for obesity drug Wegovy

https://pharmaphorum.com/news/novo-nordisk-gets-nice-okay-for-obesity-drug-wegovy/

News/ News/ R&D

Novo Nordisk moves to strengthen obesity efforts

Eloise McLennan fda, Novo Nordisk, obesity, pharma, R&D 0 Comment

After securing FDA approval for Wegovy last year, Novo Nordisk is strengthening its position in the obesity space

Novo Nordisk moves to strengthen obesity efforts

https://pharmaphorum.com/news/novo-nordisk-moves-to-strengthen-obesity-efforts/

Market Access/ News/ News

Novo Nordisk nears EU approval of obesity drug Wegovy

Phil Taylor CHMP, Novo Nordisk, obesity, Saxenda, Wegovy 0 Comment

Danish drugmaker Novo Nordisk is hoping to launch its once-weekly injectable treatment for obesity, Wegovy, in the EU

Novo Nordisk nears EU approval of obesity drug Wegovy

https://pharmaphorum.com/news/novo-nordisk-nears-eu-approval-of-obesity-drug-wegovy/

News/ News/ R&D

Regeneron, AZ team up on drugs for obesity “superpower” gene

Phil Taylor AstraZeneca, obesity, partnering, Regeneron 0 Comment

AstraZeneca has formed a partnership with Regeneron to investigate the potential of treating obesity using drugs directed at

Regeneron, AZ team up on drugs for obesity “superpower” gene

https://pharmaphorum.com/news/regeneron-az-team-up-on-drugs-for-obesity-superpower-gene/

News/ News/ Sales and Marketing

FDA ends 7-year obesity drug drought, clearing Novo Nordisk’s Wegovy

Phil Taylor Eli Lilly, Novo Nordisk, obesity, Saxenda, semaglutide, tirzepatide, Trulicity, Wegovy 0 Comment

Novo Nordisk is celebrating the FDA approval of its GLP-1 agonist semaglutide as a treatment for obesity, which

FDA ends 7-year obesity drug drought, clearing Novo Nordisk’s Wegovy

https://pharmaphorum.com/news/fda-ends-obesity-drug-drought/

Trending

obesity

Login